Posts
BDTX looks worth keeping on the watchlist heading into ASCO.
Black Diamond Therapeutics recently reported positive Phase 2 data for **silevertinib**, its brain-penetrant EGFR inhibitor for frontline NSCLC patients with **EGFR non-classical mutations**. High-level results from the May update: * **Preliminary median PFS: 15.2 months** * **Median DOR not reached** * **60% ORR** * **91% disease control rate** * **86% …
29 may , what are the biggest losers Pre-market ?
# Top Losers (Biggest Losers) |Rank|Ticker|% Change|Price|Volume|Why / Notes| |:-|:-|:-|:-|:-|:-| |1|**ZCMD**|**-65.14%**|$0.54|\~2M|Sharp drop, possibly post-rally profit taking or bad news.| |2|**SUGP**|**-44.09%**|$1.49|\~2.2M|Heavy selling pressure.| |3|**PLAB**|**-36.42%**|$34.02|10.5M|Significant decline on higher volume (more established company).| |4|**AMSS**|**-25.44%**|$4.25|\~900K|Continuation of weakness.| |5|**HDRN**|**-24.75%**|$3.01|\~500K|Down sharply.| Other losers: **PNRG** (-23.89%), **WCT**, **GMM**.
29 may 2026 , what are the biggest winners Pre-market
|Rank|Ticker|% Change|Price|Volume|Why / Notes| |:-|:-|:-|:-|:-|:-| |1|**MASK**|**+199.28%**|$4.13|149M+|Massive surge, likely news, short squeeze, or hype. Extremely high volume.| |2|**CGTL**|**+151.49%**|$0.70|119M+|Huge retail momentum play. Very low-priced stock with explosive volume.| |3|**SPRC**|**+140.32%**|$10.55|35M+|Strong buying interest, possibly sector/news driven.| |4|**ASTC**|**+113.11%**|$29.43|48M+|Major move (space/tech related themes active lately).| |5|**ATPC**|**+112.98%**|$6.07|54M+|Another low-float/high-momentum name.|
Bullish case for $CXAI
$CXAI bull case is relatively straightforward: tiny valuation, real enterprise AI software, and a market still pricing the company like execution will fail. Recent quarterly revenue was only around $950K, but the more interesting metrics were: \~98% subscription revenue \~83% gross margins \~$1.4M bookings and over $5M in new multi-year …
RXRX Continuation: Yesterday Hit $3.50 — Now I’m Watching the Failed-Squeeze Retrace
🐻 **Bearish / cautious short-term** 🐻 Ticker: **RXRX** Company: **Recursion Pharmaceuticals** Current setup: **failed-squeeze / retrace watch** Bias: **bearish short-term unless bulls reclaim strength** Key breakdown area: **$3.10 / $3.00** Primary downside target: **$2.87–$2.80** Stretch target: **$2.60** Invalidation: **reclaim and hold above $3.35–$3.50** Yesterday was a bloodbath for early shorts. …
$HOLO DD: HOLO Cross-Border Audit & Listing Trail
QTEX Just Entered Price Discovery. This Is Where Things Get Interesting 🚨‼️‼️‼️
Everyone is focused on the percentage gain. I’m focused on the chart. QTEX is now pushing into territory it has never traded in before. Not a 52-week high. Not a recent high. An actual all-time high breakout. Why does this matter? • No historical resistance above current price • No …
$HOLO DD: Public Filings, Convertible Notes, Dilution Risk, and Corporate Structure
Broadvision Intelligence (Hong Kong), Ltd. Hong Kong subsidiary 100% owned by Shenzhen BroadVision Technology Co., Ltd. Disclosed status: No operation The key questions are: reverse splits, convertible-note history, dilution risk, cash accessibility, business substance, and who benefited from the structure. If the company can clearly explain those issues, that would …
The Lounge
Talk about your daily plays, ideas and strategies that do not warrant an actual post. This is the place to request buy/sell advice from the community. Remember to keep it civil. Trade responsibly.
VCIG Earnings Tomorrow….Am I Crazy or Is This Thing Still Stupidly Undervalued?
Not financial advice. Just sharing what I’m seeing before earnings tomorrow. I’ve been digging through VCIG’s numbers and I’m trying to figure out if the market is missing something here. Current stats: Market Cap: \~$17.7M Revenue (TTM): \~$138.6M Net Income (TTM): \~$26.9M EBITDA: \~$27.3M Cash: \~$23.1M Debt: \~$2.8M Profit Margin: …